CTLA4 and melanoma: A single-institution, retrospective study of 32 melanoma patients treated using CTLA-4 inhibition and sargramostim reported an acceptable ORR and toxicity profile in this high-risk patient population (41% with CNS metastases) and with ipilumumab (3 mg/kg/dose) [101], which is lower than the Hodi et al. [99] and Kwek et al. [100] trials (ipilimumab 10 mg/kg/dose) (Table 4).